Year: 2026
Type: article
Abstract: Fibroblast activation protein-a (FAP) is a serine protease overexpressed by cancer-associated fibroblasts and linked to poor clinical outcomes. FAP-targeted radiopharmaceuticals enable imaging of metastatic castration-resistant prostate cancer. While 89Zr-DFO (t1/2 = 3.27 d) is widely used for immunoPET, many therapeutic agents will rely on DOTA to complex heavier metals with varying coordination chemistries. 52gMn (t1/2 =5.6 d) offers a half-life suitable for antibodies with long circulation times and potential theranostic pairing.
Source: ESMO Open
Authors: K. Barrett, J. Gallant, K. Ott, A. Lebeau, J. Engle
Institutions: University of Wisconsin–Madison, University of Washington
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7147419766
FWCI:
Cites:
Cited by:
Related to: